---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-053916"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:04:06.552766+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt

## Summary
- Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.
- Entire unpaid principal balance of $3.8M now due 91 days after senior debt fully paid and loan agreement terminated.
- Prior maturity triggers from capital raises, debt/equity issuance, or royalty monetization eliminated.
- New voluntary conversion feature allows parent to convert principal into shares at $0.90 per share, subject to subsidiary approval.
- Note subordinated to Avenue Venture Opportunities Fund's senior debt; cash prepayment prohibited before new maturity.

## SEC filing metadata
- accession: 0001213900-26-053916
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/0001213900-26-053916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/ea0289731-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-053916
- JSON: https://secwatch.observer/filing/0001213900-26-053916.json
- Plain text: https://secwatch.observer/filing/0001213900-26-053916.txt

## Source-grounded claims
- claim_id: 4f4c1725378ab04f777d1f1d5b5cff8b08a15da9
  claim: Citius Pharmaceuticals, Inc. amended Third Amendment to Promissory Note with Citius Oncology, Inc. (effective 2026-05-04).
  evidence_excerpt: the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory Note”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390026053916/0001213900-26-053916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.